Spotlight on KRAS G12C: Biomarker Testing Considerations in the NSCLC Landscape

Host: Paul Doghramji, MD <br> Guest: Alex Spira, MD, PhD, FACP <br> Guest: John Longshore, PhD, FACMG <br> <p>In the current era of cancer care, we’ve come to realize that non-small cell lung cancer is a disease of the genome. And now that advances in genomic profiling have enabled the identification of emerging biomarkers such as <em>KRAS G12C</em> oncologist Dr. Alex Spira and pathologist Dr. John Longshore are here to give us a closer look at the guideline recommendations for biomarker testing as well as best practices for overcoming real-world issues.</p> <p align="right">© 2020 Amgen Inc. All rights reserved. USA-510-80117 10/2020</p>